Clinical Trials Logo

Recurrent Marginal Zone Lymphoma clinical trials

View clinical trials related to Recurrent Marginal Zone Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06300528 Not yet recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma

Start date: April 30, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well pemigatinib works in treating patients with mantle cell lymphoma (MCL) or marginal zone lymphoma (MZL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Pemigatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.